CACLP Announces New Date and Venue for the Highly Anticipated 2025 Event

Impressive numbers from CACLP 2024
In March 2024, the tradeshows were a resounding success, showcasing a diverse array of products and technologies from participants. The events drew an impressive 1,346 exhibitors and 42,751 visitors from China and 40 other countries, all gathered in a sprawling exhibition space of 130,000 sqm.

A series of academic activities featured 125 scientific lectures with 315 academic speakers and attracted over 5,000 delegates. These activities garnered 462,150 online views through CACLP’s WeChat channels and app.

Hangzhou: the ideal host for CACLP 2025
The upcoming event will return to Hangzhou, offering global participants a convenient and enriching experience in the newly opened Hangzhou Grand Convention & Exhibition Center.

Located in the heart of the economically vibrant Yangtze River Delta, Hangzhou offers convenient transportation, advanced innovation, and abundant natural and cultural resources. This enchanting city provides an ideal environment for the IVD industry. There are 6,626 medical and healthcare institutions in Hangzhou, including 414 hospitals and 27 top-tier (Grade A, Level 3) hospitals. Hangzhou has also pioneered China’s first dedicated IVD industry promotion institute to bolster local industry development. 

With China’s favorable visa-free policy, international participants will find it easier than ever to join, and discover an optimal setting for collaboration, extensive networking, and exploration of the latest market trends and innovations. 

Academic Highlights in Hangzhou
Numerous professionals across the whole IVD industry chain are expected take part in the concurrent academic activities, such as the 10th China Experimental Medicine Conference (CEMC) and series sessions and the 12th China IVD Industry Development Conference (CIIDC) and series forums.

These activities will include in-depth discussions on hot topics in laboratory medicine and IVD, with renowned experts and scholars presenting cutting-edge research findings, while industry leaders exchange valuable experiences.

 "Bringing IVD people together!" embodies our commitment to always foster unity and progress within the industry. Join us in Hangzhou for CACLP 2025!

Interested in exhibiting or seeking more information? Leave your message here and we will get back to you very soon: https://en.caclp.com/exhibit-reserve.html


About GL events
GL events is a world-class leading provider of integrated solutions and services for events operating across the 3 major core divisions: Venues (venue management), Exhibitions (exhibition organizing) and Live (event services).
Through its wide global network made up of more than 90 offices, with organizing over 480 proprietary trade fair and events, managing more than 60 venues, and staging more than 4,200 events every year, GL events Group is a critical force for city promotion of 28 MICE destinations.
Present on five continents with operations in more than 20 countries, GL events has over 5,119 employees. Listed on the Eurolist Euronext Compartment B (Paris Stock Exchange), GL events had a turnover of €1.315bn in 2022.

About CACLP
Debut launched in 1991, China International In Vitro Diagnostic Expo by CACLP, is well established as one of the largest exhibitions in the in vitro diagnostic industry worldwide. China IVD Supply Chain Expo, successfully launched in 2021, further expands the product sectors from upstream to downstream. With a great number of high-level academic and educational programs held concurrently onsite, and year-round promotional solutions, CACLP proves itself as one of the most important platforms for global IVD players.
In 2020, CACLP formed the joint-venture company with GL events to start the internationalism strategy.

Visit expo >

Gold Member

Pharmacogenetics Panel

VeriDose Core Panel v2.0

Gold Member

Troponin T QC

Troponin T Quality Control

New

Epstein-Barr Virus Assay

Panther Fusion EBV Quant Assay

New

C-Terminal Telopeptide ELISA

Urine BETA CrossLaps (CTX-I) ELISA